Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain

B. Costa, M. Colleoni, S. Conti, A. E. Trovato, M. Bianchi, M. L. Sotgiu, G. Giagnoni

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

The antinociceptive properties of cannabinoids in persistent pain are not fully elucidated. We investigated the effect of repeated treatment with the synthetic cannabinoid receptor agonist WIN 55,212-2 on the neuropathic pain induced in rats by chronic constriction of the sciatic nerve. WIN 55,212-2 administered daily throughout the development of neuropathy reversed the hyperalgesia, at a dose (0.1 mg kg -1, s.c.) that had no effect on the nociceptive responses of either paw contralateral to the sciatic ligation or of animals subjected to sham surgery. At 14 days after injury, the levels of mediators known to be involved in neuropathic pain, such as prostaglandin E2, NO and the neuronal NOS, were increased. Repeated treatment with WIN 55,212-2 abolished these increases. In the light of the current clinical need for neuropathic pain treatments, these findings indicate that cannabinoid agonists, at doses devoid of psychoactive effects, could constitute important compounds for the development of new analgesics.

Original languageEnglish
Pages (from-to)4-8
Number of pages5
JournalBritish Journal of Pharmacology
Volume141
Issue number1
DOIs
Publication statusPublished - Jan 2004

Fingerprint

Cannabinoids
Hyperalgesia
Neuralgia
Cannabinoid Receptor Agonists
Artificial Receptors
Sciatic Nerve
Dinoprostone
Constriction
Ligation
Analgesics
Therapeutics
Pain
Wounds and Injuries
Win 55212-2

Keywords

  • Endogenous cannabinoid system
  • Neuropathic pain
  • Nitric oxide system
  • WIN 55,212-2

ASJC Scopus subject areas

  • Pharmacology

Cite this

Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. / Costa, B.; Colleoni, M.; Conti, S.; Trovato, A. E.; Bianchi, M.; Sotgiu, M. L.; Giagnoni, G.

In: British Journal of Pharmacology, Vol. 141, No. 1, 01.2004, p. 4-8.

Research output: Contribution to journalArticle

Costa, B. ; Colleoni, M. ; Conti, S. ; Trovato, A. E. ; Bianchi, M. ; Sotgiu, M. L. ; Giagnoni, G. / Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. In: British Journal of Pharmacology. 2004 ; Vol. 141, No. 1. pp. 4-8.
@article{045be87b8e5c492396d45cdc9305f6dd,
title = "Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain",
abstract = "The antinociceptive properties of cannabinoids in persistent pain are not fully elucidated. We investigated the effect of repeated treatment with the synthetic cannabinoid receptor agonist WIN 55,212-2 on the neuropathic pain induced in rats by chronic constriction of the sciatic nerve. WIN 55,212-2 administered daily throughout the development of neuropathy reversed the hyperalgesia, at a dose (0.1 mg kg -1, s.c.) that had no effect on the nociceptive responses of either paw contralateral to the sciatic ligation or of animals subjected to sham surgery. At 14 days after injury, the levels of mediators known to be involved in neuropathic pain, such as prostaglandin E2, NO and the neuronal NOS, were increased. Repeated treatment with WIN 55,212-2 abolished these increases. In the light of the current clinical need for neuropathic pain treatments, these findings indicate that cannabinoid agonists, at doses devoid of psychoactive effects, could constitute important compounds for the development of new analgesics.",
keywords = "Endogenous cannabinoid system, Neuropathic pain, Nitric oxide system, WIN 55,212-2",
author = "B. Costa and M. Colleoni and S. Conti and Trovato, {A. E.} and M. Bianchi and Sotgiu, {M. L.} and G. Giagnoni",
year = "2004",
month = "1",
doi = "10.1038/sj.bjp.0705587",
language = "English",
volume = "141",
pages = "4--8",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain

AU - Costa, B.

AU - Colleoni, M.

AU - Conti, S.

AU - Trovato, A. E.

AU - Bianchi, M.

AU - Sotgiu, M. L.

AU - Giagnoni, G.

PY - 2004/1

Y1 - 2004/1

N2 - The antinociceptive properties of cannabinoids in persistent pain are not fully elucidated. We investigated the effect of repeated treatment with the synthetic cannabinoid receptor agonist WIN 55,212-2 on the neuropathic pain induced in rats by chronic constriction of the sciatic nerve. WIN 55,212-2 administered daily throughout the development of neuropathy reversed the hyperalgesia, at a dose (0.1 mg kg -1, s.c.) that had no effect on the nociceptive responses of either paw contralateral to the sciatic ligation or of animals subjected to sham surgery. At 14 days after injury, the levels of mediators known to be involved in neuropathic pain, such as prostaglandin E2, NO and the neuronal NOS, were increased. Repeated treatment with WIN 55,212-2 abolished these increases. In the light of the current clinical need for neuropathic pain treatments, these findings indicate that cannabinoid agonists, at doses devoid of psychoactive effects, could constitute important compounds for the development of new analgesics.

AB - The antinociceptive properties of cannabinoids in persistent pain are not fully elucidated. We investigated the effect of repeated treatment with the synthetic cannabinoid receptor agonist WIN 55,212-2 on the neuropathic pain induced in rats by chronic constriction of the sciatic nerve. WIN 55,212-2 administered daily throughout the development of neuropathy reversed the hyperalgesia, at a dose (0.1 mg kg -1, s.c.) that had no effect on the nociceptive responses of either paw contralateral to the sciatic ligation or of animals subjected to sham surgery. At 14 days after injury, the levels of mediators known to be involved in neuropathic pain, such as prostaglandin E2, NO and the neuronal NOS, were increased. Repeated treatment with WIN 55,212-2 abolished these increases. In the light of the current clinical need for neuropathic pain treatments, these findings indicate that cannabinoid agonists, at doses devoid of psychoactive effects, could constitute important compounds for the development of new analgesics.

KW - Endogenous cannabinoid system

KW - Neuropathic pain

KW - Nitric oxide system

KW - WIN 55,212-2

UR - http://www.scopus.com/inward/record.url?scp=1242296234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242296234&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0705587

DO - 10.1038/sj.bjp.0705587

M3 - Article

C2 - 14662732

AN - SCOPUS:1242296234

VL - 141

SP - 4

EP - 8

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 1

ER -